|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001675,
umls-concept:C0006826,
umls-concept:C0008625,
umls-concept:C0008626,
umls-concept:C0023418,
umls-concept:C0023449,
umls-concept:C0031525,
umls-concept:C0348801,
umls-concept:C0441836,
umls-concept:C1524062,
umls-concept:C2603343
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2004-1-13
|
|
pubmed:abstractText |
We analysed the nature and prognostic significance of secondary cytogenetic changes in 111 newly diagnosed adults with acute lymphoblastic leukaemia (ALL) and t(9;22)(q34;q11.2) or its variants. Secondary aberrations were seen in 75 (68%) patients. They included, in order of descending frequency: +der(22)t(9;22), +21, abnormalities of 9p, high hyperdiploidy (>50 chromosomes), +8, -7, +X and abnormalities resulting in loss of material from 8p, gain of 8q, gain of 1q and loss of 7p. Eighty patients (72%) had > or =1 normal metaphase in their karyotype. There were four balanced and 12 unbalanced translocations previously unreported in ALL with t(9;22). The t(2;7)(p11;p13) and der(18)t(8;18)(q11.2;p11.2) were seen in two cases each, and have never before been reported in haematological malignancy. All but four patients were treated on front-line Cancer and Leukaemia Group B clinical protocols. The presence of -7 as a sole secondary abnormality was associated with a lower complete remission (CR) rate (P = 0.004), while the presence of > or =3 aberrations was associated with a higher CR rate (P = 0.009) and +der(22)t(9;22) with a higher cumulative incidence of relapse (P = 0.02). It will be of interest to see if newly diagnosed t(9;22)-positive adult ALL patients with these and other secondary aberrations respond differently to treatment regimens that include imatinib mesylate.
|
|
pubmed:grant |
http://linkedlifedata.com/resource/pubmed/grant/CA 02599,
http://linkedlifedata.com/resource/pubmed/grant/CA 03927,
http://linkedlifedata.com/resource/pubmed/grant/CA 04326,
http://linkedlifedata.com/resource/pubmed/grant/CA 04457,
http://linkedlifedata.com/resource/pubmed/grant/CA 07968,
http://linkedlifedata.com/resource/pubmed/grant/CA 101140,
http://linkedlifedata.com/resource/pubmed/grant/CA 11028,
http://linkedlifedata.com/resource/pubmed/grant/CA 11789,
http://linkedlifedata.com/resource/pubmed/grant/CA 12046,
http://linkedlifedata.com/resource/pubmed/grant/CA 12449,
http://linkedlifedata.com/resource/pubmed/grant/CA 16058,
http://linkedlifedata.com/resource/pubmed/grant/CA 16450,
http://linkedlifedata.com/resource/pubmed/grant/CA 21060,
http://linkedlifedata.com/resource/pubmed/grant/CA 26806,
http://linkedlifedata.com/resource/pubmed/grant/CA 31809,
http://linkedlifedata.com/resource/pubmed/grant/CA 31946,
http://linkedlifedata.com/resource/pubmed/grant/CA 32291,
http://linkedlifedata.com/resource/pubmed/grant/CA 33601,
http://linkedlifedata.com/resource/pubmed/grant/CA 35279,
http://linkedlifedata.com/resource/pubmed/grant/CA 35406,
http://linkedlifedata.com/resource/pubmed/grant/CA 37135,
http://linkedlifedata.com/resource/pubmed/grant/CA 41287,
http://linkedlifedata.com/resource/pubmed/grant/CA 45418,
http://linkedlifedata.com/resource/pubmed/grant/CA 47545,
http://linkedlifedata.com/resource/pubmed/grant/CA 47555,
http://linkedlifedata.com/resource/pubmed/grant/CA 47559,
http://linkedlifedata.com/resource/pubmed/grant/CA 47577,
http://linkedlifedata.com/resource/pubmed/grant/CA 47642,
http://linkedlifedata.com/resource/pubmed/grant/CA 77440,
http://linkedlifedata.com/resource/pubmed/grant/CA 77658
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0007-1048
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
124
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
275-88
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:14717774-Adult,
pubmed-meshheading:14717774-Aged,
pubmed-meshheading:14717774-Antineoplastic Agents,
pubmed-meshheading:14717774-Chromosome Aberrations,
pubmed-meshheading:14717774-Chromosomes, Human, Pair 2,
pubmed-meshheading:14717774-Chromosomes, Human, Pair 22,
pubmed-meshheading:14717774-Chromosomes, Human, Pair 7,
pubmed-meshheading:14717774-Chromosomes, Human, Pair 9,
pubmed-meshheading:14717774-Female,
pubmed-meshheading:14717774-Humans,
pubmed-meshheading:14717774-Karyotyping,
pubmed-meshheading:14717774-Male,
pubmed-meshheading:14717774-Middle Aged,
pubmed-meshheading:14717774-Piperazines,
pubmed-meshheading:14717774-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:14717774-Prognosis,
pubmed-meshheading:14717774-Prospective Studies,
pubmed-meshheading:14717774-Pyrimidines,
pubmed-meshheading:14717774-Recurrence,
pubmed-meshheading:14717774-Remission Induction,
pubmed-meshheading:14717774-Translocation, Genetic
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B.
|
|
pubmed:affiliation |
Department of Medicine, Leukemia Section, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA. meir.wetzler@roswellpark.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
